Leading drugmakers rushing to increase subsidiaries

Korea’s major drug firms have increased their number of affiliates, an expansion that is feared will divert them from their core businesses and weaken their competitiveness.

According to the Ministry of Health and Welfare and the Financial Supervisory Service, the top 10 pharmaceutical companies have seen their combined number of affiliates rise up to 97, showing an average 10 subsidies per ...